14/03/2019 22:45:45

Syneos Health Schedules Fourth Quarter and Year End 2018 Earnings Call for Monday, March 18, 2019

MORRISVILLE, N.C., March 14, 2019 (GLOBE NEWSWIRE) -- Syneos Health™ (Nasdaq: SYNH), the only fully integrated biopharmaceutical solutions organization combining a Contract Research Organization (CRO) and Contract Commercial Organization (CCO), will release its fourth quarter and year end 2018 financial results and file its Form 10-K for the fiscal year ended December 31, 2018, after the market closes on Monday, March 18, 2019. The Company will host its earnings call at 5:30 p.m. ET that afternoon.

Participants may access the conference call live via webcast on the Investor Relations section of the Syneos Health website at investor.syneoshealth.com. To participate via telephone, please dial +1 877 930 8058 within the United States or +1 253 336 7551 outside the United States, approximately 15 minutes prior to the scheduled start time. The conference ID for the call is 3768756.

A webcast replay will be available on the Investor Relations section of the Syneos Health website at investor.syneoshealth.com after 8:30 p.m. on March 18. In addition, an audio replay will be available for one week following the call and will be accessible by dialing +1 855 859 2056 within the United States or +1 404 537 3406 outside the United States. The replay ID is 3768756.

About Syneos Health

Syneos Health™ (Nasdaq:SYNH) is the only fully integrated biopharmaceutical solutions organization. Our company, including a Contract Research Organization (CRO) and Contract Commercial Organization (CCO), is purpose-built to accelerate customer performance to address modern market realities. Created through the merger of two industry leading companies – INC Research and inVentiv Health – we bring together more than 23,000 clinical and commercial minds with the ability to support customers in more than 110 countries. Together we share insights, use the latest technologies and apply advanced business practices to speed our customers’ delivery of important therapies to patients. To learn more about how we are shortening the distance from lab to life® visit syneoshealth.com.

   

Investor Relations Contact:

 

Press/Media Contact:

Ronnie Speight Danielle DeForge
Senior Vice President, Investor Relations Executive Director, External Communications
+1 919 745 2745 +1 781 425 2624

investor.relations@syneoshealth.com

 

danielle.deforge@syneoshealth.com

   

Syneos Health_rgb_tm.png

Del

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
18 Aug
VELO
Da flere skribenter stadig gerne vil beholde tråden for samling af de mange vigtige informationer o..
44
19 Aug
OMXC25
Endnu en dansk patriark er død. Ære være hans minde.
28
18 Aug
 
Da Berlingske Media for cirka 1 år siden overtog Euroinvestor for 23 mio kr, meddelte de, at nu skul..
22
20 Aug
VELO
Ny artikel på Medwatch:   15,5 pct. af amerikanske patienter, der får en nyretransplantation i dag, ..
20
18 Aug
VELO
Fra anden skribent i Veloxis FB gruppen: Børsen side 4, søndag den 18. august. Et uddrag fra e..
20
21 Aug
I:NDX
Trump er en forretningsmand, der bevæger sig med en forretningsmands hastighed. Han er fløjtende lig..
18
20 Aug
PNDORA
  har du læst regnskabet - de forventer at tjene 4 mia i 2019 i forhold til en værdi af selskabet på..
18
19 Aug
OMXC25
En fantastisk dygtig og sympatisk erhvervsmand.  Og en ægte patriot som også betalte sin skat med gl..
17
16 Aug
I:NDX
17
20 Aug
GEN
Lige i dette tilfælde er der måake ikke det vilde nye - men det er stadig data på disse konference d..
15

#

EuroInvestor: In Focus
#

#

EuroInvestor: In Focus
#

#

EuroInvestor: In Focus
#

Most read news

  • 24 hours
  • 48 hours
  • 1 week
1
Avinger Prices $4.5 Million Underwritten Public Offering of Common Stock
2
MYGN Loss Alert: Hagens Berman Investigating Myriad Genetics (MYGN) For Possible Disclosure Violations
3
Bone Therapeutics SA to report half year 2019 results on 30 August 2019
4
Genmab Announces Approval of DARZALEX® (daratumumab) in Frontline Multiple Myeloma in Japan
5
Ambu A/S: Interim report for Q3 2018/19

Copyright Berlingske Media 2019  Cookie- and Privacy policy  |  Cookies  |   General terms of trade  |   Terms of use and IP rights
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
22 August 2019 08:50:14
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20190819.1 - EUROWEB7 - 2019-08-22 09:50:14 - 2019-08-22 08:50:14 - 1000 - Website: OKAY